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Abstract 
Background: There is limited data on factors associated with loss to follow-up (LTFU) of health care workers (HCWs) 
following occupational exposure to HIV, and most studies were conducted in an era when poorly tolerated antiretro-
virals like zidovudine were used.
Methods: A retrospective cohort study was conducted of HCWs attending a referral hospital’s Occupational Health 
Clinic in Cape Town, South Africa for post-exposure prophylaxis (PEP) during a period when tenofovir was available. 
Our primary outcome was LTFU at the 3-month visit. We selected seven variables a priori for our logistic regression 
model and ensured there were at least 10 outcome events per variable to minimize bias.
Results: Two hundred and ninety-three folders were evaluated for descriptive analysis. LTFU worsened with succes-
sive visits: 36% at 6 weeks, 60% at 3 months, and 72% at 6 months. In multivariate analysis at the 3-month visit LTFU 
was associated with age (adjusted odds ratio (aOR), 0.6 per 10-year increase [95% CI, 0.5–0.9]), HCW category of doctor 
(aOR 2.7 [95% CI, 1.3–5.5]), and time from exposure to receiving PEP of more than 24 h (aOR 5.9 [95% CI, 1.3–26.9]).
Conclusion: We identified factors associated with LTFU of HCWs after occupational HIV exposure, which could be 
used to target interventions to improve follow-up.
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Background
The World Health Organization (WHO) estimates 3 
million occupational human immunodeficiency virus 
(HIV) percutaneous exposures occur among 35 million 
healthcare workers (HCWs) annually, with 90% of expo-
sures occurring in resource limited settings [1]. HCWs 
exposed to potentially infectious material from a source 
patient with HIV infection, or unknown HIV status, are 
offered post-exposure prophylaxis (PEP) if this is appro-
priate, and attend several follow-up visits for PEP toxic-
ity monitoring and exclusion of HIV infection. Although 
HIV seroconversion following occupational exposure 
is uncommon, early diagnosis is critical as treatment of 
early HIV infection reduces the risk of HIV transmission 
and has direct benefits for the individual by reducing 
morbidity and mortality [2, 3].
Attendance of HCWs to follow-up visits after occupa-
tional exposure to HIV has been highly variable, rang-
ing from 0 to 98.9% in observational studies [4–13]. A 
literature search yielded three studies that evaluated fac-
tors associated with attendance to follow-up [6, 12, 13]. 
Two studies found that the type of HCW category did 
not influence attendance to follow-up, [12, 13] but one 
study found that HCW category did influence attend-
ance to follow-up [6]. One study identified being exposed 
to an HIV seropositive source increased attendance to 
follow-up, [13] but another found this had no effect [6]. 
One study [13] reported that type of exposure and time 
to reporting did not influence attendance to follow-up; 
and women had better attendance to follow-up than 
men [13]. Sample size calculations were not reported in 
any of these three studies. Furthermore, many of the PEP 
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regimens used in these studies included poorly tolerated 
antiretroviral drugs. A recent systematic review reported 
that tenofovir disoproxil fumarate (TDF) based PEP was 
better tolerated with higher completion rates than zido-
vudine based PEP, which used to be the standard of care 
[14]. The WHO now recommends the use of TDF as part 
of the backbone for PEP regimens [15].
We aimed to evaluate factors associated with loss to 
follow-up (LTFU) following occupational exposure to 
HIV in a referral hospital in Cape Town, South Africa, 
where the HIV prevalence is 12.7% [16]. We conducted 
our study in a period when we switched to TDF based 
PEP, and ensured we had sufficient power to determine 
variables associated with LTFU.
Methods
Study setting
Data was collected from the Occupational Health Clinic 
(OHC) of Groote Schuur Hospital, a referral hospital in 
Cape Town, South Africa. HCWs who have significant 
occupational HIV exposure are started on PEP if they 
present within 72  h of the exposure. During the study 
period the South African national guidelines for PEP rec-
ommended the use of TDF and emtricitabine for expo-
sures presenting within 72 h. The policy of adding a 3rd 
antiretroviral (usually a boosted protease inhibitor) was 
changed during the study period: initially this was added 
only for high risk exposures, but subsequently this was 
added for all exposures. HCWs are counselled about the 
risks of HIV, the need to document HIV testing for pos-
sible compensation, and potential adverse drug reactions 
to PEP. HIV status of the HCW was determined at base-
line using 4th generation Roche COBAS HIV-1/2 Combo 
automated test with a confirmatory Siemens Integral 
4th generation ELISA. PEP was discontinued in HCWs 
who tested HIV seropositive at baseline. HIV testing was 
repeated at week 6 (when HCWs were informed that HIV 
tests may be false negative), and months 3 and 6 after the 
exposure. Confidentiality of HCWs is protected by keep-
ing all files in the OHC and not in the general records 
department; only OHC clinic staff are able to access the 
files.
Study design
We conducted a retrospective cohort review to identify 
the factors associated with LTFU in HCWs following 
occupational HIV exposure. The OHC maintains an elec-
tronic database of all visits related to HCW occupational 
HIV exposures. We collected data from the database and 
additional data from folders between January 2013 and 
September 2015, with 29 additional folders obtained in 
2012.
Outcomes
The primary outcome was the proportion of HCWs 
LTFU at the 3-month visit, which is the key follow-up 
date to determine if HIV seroconversion has occurred, in 
keeping with the WHO guidelines [15]. Secondary out-
comes were the proportion of HCWs LTFU at the 6-week 
and 6-month visits.
Data collection
Data collection at the OHC is collated from an “Occupa-
tional Health Clinic Percutaneous Inoculation Report” 
form. The data are collected each time the HCW presents 
for follow-up or when contacted by telephone. This form 
is completed by the occupational health worker on duty, 
who is either the nurse or doctor. Once 6  months have 
lapsed since the last visit, the data collected are recorded 
in an electronic database using Microsoft Excel and 
HCW folders are then archived in the clinic.
Study population
Inclusion criteria
HCWs were categorized into three groups: ‘Doctors’, 
‘Students’ and ‘Allied Health Professionals’ (e.g. nursing, 
physiotherapists, occupational therapists, administrative 
clerks, pharmacists, and emergency medical services). 
HCWs were included if they were exposed to potentially 
infectious material from patients who are HIV-infected 
or HIV status unknown and attended the OHC. The fol-
lowing materials were deemed to be potentially infec-
tious: pleural, pericardial, peritoneal, cerebrospinal, 
synovial fluid, amniotic fluid, and blood [17].
Exclusion criteria
Exclusion criteria were: HCW tested HIV seropositive 
at baseline; exposed to a HIV seronegative source; those 
who requested follow-up at a private doctor or who went 
back to their own training institutions, such as elective 
students; multiple exposures within the 6-month follow-
up period; exposures deemed to be from non-infectious 
material [17].
Sample size estimation
We selected seven variables a priori for inclusion into 
our model based on our review of the literature: age at 
exposure, sex, HCW category, type of exposure, source 
patient HIV status, dual or triple antiretroviral therapy 
(ART), and time from exposure to time of receiving PEP. 
Assuming 25% LTFU at 3  months, [12] we required a 
sample size of 280 to ensure a minimum of 10 outcome 
events per variable, which are needed to improve pre-
cision and minimize bias in logistic regression models 
[18].
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Statistical analysis
All statistical analysis was performed using Stata (Ver-
sion 13.1; Stata Corp, College Station, Texas, USA). 
Descriptive statistics were used to characterize the total 
sample, and results were expressed as median (interquar-
tile range) for non-normally distributed continuous vari-
ables, and frequencies and percentages for categorical 
variables.
We used separate multivariable logistic regression 
models for each time point to identify factors associated 
with LTFU at the 3-month, 6-week, and 6-month follow-
up visits. The full model approach was utilized using a 
priori selected variables in order to ensure decreased 
risk of selection bias and overfitting [19]. This approach 
allows multiple epidemiological variables to be assessed 
independently while controlling effects of other variables 
[20]. Univariate analysis was used to estimate crude odds 
ratios (ORs) and 95% confidence intervals (95% CIs), 
while multivariable logistic regression provided adjusted 
estimates for odds of LTFU at each time point. Odds 
ratios were presented with 95% CIs and a level of P < 0.05 
was considered statically significant.
Results
Two hundred and sixty-four folders were obtained 
between January 2013 and September 2015, with an addi-
tional 29 folders collected according to alphabetical order 
in 2012. There was incomplete data on 12 HCWs who were 
included in the descriptive analysis but excluded from the 
univariate and multivariate analysis as shown in Fig. 1.
The characteristics of the 293 patients from our cohort 
are shown in Table  1. The dual nucleotide/nucleoside 
reverse transcriptase inhibitors used in PEP were TDF 
(97%), zidovudine (2%), and stavudine (1%); all of which 
were combined with either lamivudine or emtricitabine. 
The third agent used in 210 HCWs who were given triple 
ART was lopinavir/ritonavir (82%), atazanavir/ritonavir 
(13%), raltegravir (4%), and efavirenz (1%).
LTFU at the various visits were: 36% at 6  weeks, 60% 
at 3 months, and 72% at 6 months (Table 1). The univari-
ate and multivariate analysis of variables associated with 
LTFU at the 3-month visit are shown in Table 2. In the 
multivariate analysis, significant risk factors associated 
with LTFU were: younger age, HCW category of doc-
tor, and time from exposure to receiving PEP of more 
than 24  h. The multivariate analysis of variables associ-
ated with LTFU at the 6-week and 6-month follow-up 
visits are shown in Table  3. Variables associated with 
LTFU at the 6-week visit were: male sex and HCW cat-
egory of doctor. Variables associated with LTFU at the 
6-month visit were similar to the 3-month visit: younger 
age, HCW category of doctor, and time from exposure to 
receiving PEP of more than 24 h.
LTFU by category of HCW at the various visits is 
shown in Fig. 2, with doctors having the highest propor-
tion LTFU.
293 folders reviewed for 
descriptive analysis 
12 folders excluded due to missing data:
• Health care worker (n=1)
• Type of exposure (n=7)
• Antiretroviral therapy (n=1)
• Time from exposure to time of receiving PEP 
(n=2)
• Patient did not receive PEP because presented 
after 72 hours following exposure (n=1)281 folders reviewed for 
univariate and 
multivariate analysis 
Fig. 1 Flow chart illustrating data set of health care workers chosen 
for analysis
Table 1 Baseline characteristics and  follow-up of  293 
health care workers with occupational exposure
Number with missing data: a n = 1, b n = 7, c n = 1, d n = 2, e n = 12
f  One health care worker did not receive PEP because presented too late
Variable Sample (n)
Age, median (IQR) 28 (24–35)
Sex
 Women 197 (67%)
 Men 96 (33%)
Health care  workera
 Allied health professional 85 (29%)
 Doctor 100 (34%)
 Student 107 (37%)
Type of  exposureb
 Hollow-bore 137 (48%)
 Mucocutaneous 86 (30%)
 Solid sharp 63 (22%)
Source patient HIV status
 Positive 246 (84%)
 Unknown 47 (16%)
Antiretroviralc,f
 Dual 81 (28%)
 Triple 210 (72%)
Time from exposure to receiving  PEPd (h)
 <24 268 (92%)
 24–48 17 (6%)
 48–72 1 (0.3%)
 >72 4 (1.4%)
Loss to follow-upe
 6 weeks 100 (36%)
 3 months 169 (60%)
 6 months 203 (72%)
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Discussion
We showed that LFTU of HCWs after occupational HIV 
exposure was high and increased with successive visits. 
Younger age, the HCW category doctor, and time from 
exposure to receiving PEP of more than 24 h were associ-
ated with LTFU at the 3-month visit, which was our pri-
mary endpoint. Men were more likely to be LTFU at the 
6-week visit than women. These findings could be used to 
target interventions designed to improve follow-up.
Our finding that LTFU increases with successive visits 
is consistent with other studies [9, 12, 13]. We found that 
younger age was a significant risk factor for LTFU, which 
is in keeping with other studies [21–23]. The higher LTFU 
in younger HCWs may be related to the greater change 
and instability they experience in their younger years [24]. 
Men tended to be more likely to be LTFU in our study, 
which is similar to the findings of Escurdero et al. [13].
The majority (207 out of 281) of HCWs in our study 
were doctors and students. Doctors and students are 
often involved in invasive medical procedures, which 
places them at risk of being exposed to infectious mate-
rial [7, 9, 11, 25]. Furthermore, students and doctors with 
less than a year’s experience, are prone to occupational 
exposure because of their inexperience [7, 9, 26]. We 
found that doctors are more likely to be LTFU than other 
HCW categories. This could be explained by the ease 
with which doctors can submit their own blood samples 
for HIV testing instead of attending the OHC. One study, 
[27] showed a large proportion of HCWs obtained HIV 
testing outside of the facility where they worked, which 
they suggested was due to concern surrounding the confi-
dentiality of HIV testing at the facility. Furthermore, doc-
tors may be making their own assessment of the severity 
of the exposure and may deem it unnecessary to follow-
up [28]. In contrast to our findings of increased LTFU in 
doctors, Gutierrez et  al. [6] showed cleaning personnel 
were more likely to be LTFU. Two other studies found 
type of HCW category did not influence attendance to 
follow-up [12, 13].
Longer time from exposure to receiving PEP at the 
3-month visit was positively associated with LTFU. This 
could be explained by HCWs who present after 24 h hav-
ing a perceived lower benefit from PEP. However, type of 
exposure and source patient HIV status, which are asso-
ciated with risk of HIV acquisition, were not associated 
with LTFU in our cohort.
Escudero et  al. [13] also found that type of exposure 
was not related to attendance to follow-up. Findings from 
studies that assessed the effect of the source patient’s HIV 
status on LTFU are contradictory, with one study report-
ing no effect, [6] while another found positive serological 
status was associated with improved follow up [13].
Table 2 Variables associated with loss to follow-up at 3 months
a  Reference category
Variables Unadjusted OR (95% CI) P value Adjusted OR (95% CI) P value
Age (per 10-year increase) 0.7 (0.5–0.9) 0.003 0.6 (0.5–0.9) 0.011
Sex
 Women a
 Men 1.4 (0.8–2.4) 0.190 1.4 (0.8–2.5) 0.262
Health care worker
 Allied health  professionala
 Doctor 2.9 (1.6–5.4) 0.001 2.7 (1.3–5.5) 0.006
 Student 2.0 (1.1–3.6) 0.022 1.2 (0.6–2.6) 0.584
Type of exposure
 Hollow-borea
 Mucocutaneous 1.6 (0.9–2.9) 0.095 1.1 (0.6–2.2) 0.707
 Solid sharp 1.3 (0.7–2.4) 0.377 1.0 (0.5–1.9) 0.948
Source patient HIV status
 Positive 0.9 (0.4–1.8) 0.742 0.5 (0.2–1.1) 0.074
 Unknowna
Antiretroviral
 Dual 1.4 (0.8–2.3) 0.250 1.5 (0.8–2.8) 0.228
 Triplea
Time from exposure to receiving PEP (h)
 <24a
 >24 3.0 (1.0–9.2) 0.052 5.9 (1.3–26.9) 0.023
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There are a number of studies which reported that dual 
ART regimens are better tolerated than triple regimens 
[29, 30]. However, many of these studies include ART 
that are no longer used due to toxicity. Newer studies 
have shown that completion of PEP is based on the toler-
ability of ART and not on whether dual or triple therapy 
are used [31, 32]. This could explain why in our cohort 
there was no correlation between type of ART used and 
LTFU.
There were several limitations of our study. First, the 
retrospective cohort design is inherently prone to bias. 
However, the data was captured by OHC staff on a stand-
ard form and we had very little missing data. Second, 
although we found that time from exposure to receiving 
PEP was associated with LTFU, the 95% CIs were wide 
due to the small sample size of HCWs with delayed pres-
entation. Third, we did not explore associations between 
years of HCW experience and exposure as we did not 
have this data. Other researchers have reported an asso-
ciation between years of experience and the incidence of 
occupational exposures [7, 9, 25]. Finally, Groote Schuur 
Hospital is a tertiary facility with referrals from other 
hospitals that fall under the University of Cape Town, so 
our findings may not be generalizable to other settings 
such as district hospitals.
We have identified factors associated with LTFU, which 
could be used to target interventions to decrease LTFU. 
In one study, [13] contacting HCWs by telephone or 
mail improved attendance to follow-up from 33 to 54%. 
Schmid et  al. [33] suggested attendance to follow-up 
could be improved with fewer follow-up visits. The WHO 
has recently advised the final follow-up visit should be at 
3 months rather than 6 months [15]. Furthermore, it has 
been suggested that the last follow-up visit should be at 
6 weeks if laboratory 4th generation HIV ELISA tests are 
utilized, and 8 weeks if 4th generation rapid HIV tests are 
utilized [34]. Lastly van der Maaten et  al. [9] suggested 
increasing awareness of the availability of PEP through 
campaigns.












Age (per 10-year increase) 1.0 (0.7–1.3) 0.764 0.6 (0.5–0.9) 0.010
Sex
 Womena
 Men 1.8 (1.1–3.2) 0.027 1.8 (0.9–3.4) 0.082
Health care worker
 Allied health 
 professionala
 Doctor 2.1 (1.1–4.4) 0.034 2.1 (1.0–4.5) 0.049
 Student 1.1 (0.5–2.5) 0.750 1.3 (0.6–2.9) 0.532
Type of exposure
 Hollow-borea
 Mucocutaneous 1.0 (0.5–1.9) 0.988 1.2 (0.6–2.5) 0.659
 Solid sharp 1.1 (0.5–2.1) 0.857 1.1 (0.5–2.4) 0.728
Source patient HIV status
 Positive 1.0 (0.5–2.2) 0.952 0.7 (0.3–1.7) 0.489
 Unknowna
Antiretroviral
 Dual 1.2 (0.6–2.3) 0.544 0.7 (0.4–1.4) 0.333
 Triplea
Time from exposure to receiving PEP (h)
 <24a





















Allied Health Professionals Doctors Student
Fig. 2 Percentage loss to follow-up (LTFU) by number of visits of various health care worker categories (visits were scheduled at 6 weeks, 3 months, 
and 6 months). Error bars are shown
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Conclusion
We have identified factors associated with LTFU of 
HCWs after occupational HIV exposure. Future research 
should identify measures to improve attendance to fol-
low-up, which could be targeted at doctors, younger 
HCWs, and HCWs with delayed presentation.
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